Arrhythmogenic Cardiomyopathy
The research project, named IMPACT - Cardiogenomics meets Artificial Intelligence: a step forward in arrhythmogenic card…
Meet us at BIO in Boston from June 5th to 8th, 2023!
Ksilink is attending this year’s BIO Convention 2023 from June 5th to 8th 2023 in Boston, US with 3 delegates. We will take part in the French delegation of over 100 biotech companies and attend the partnering and French pavillon booth nr. 951. Meet us in Boston and learn more how we drive patient-based drug discovery solutions to fight cardio, muscular and neurological disorders.
environMENTAL - New EU-Funded project reveals the role of environMENTAL factors for mental illnesses
The EU-funded project environMENTAL is holding its kick-off meeting to initiate its investigation on the influence of gl…
Myrtil Biotechnologies - innovative Arzneimittelforschung für Patienten mit dilatativer Kardiomyopathie
Im Rahmen einer langfristigen Zusammenarbeit haben Ksilink und myriamed gemeinsam ein aus induzierten pluripotenten Stam…
Myrtil Biotechnologies – innovating drug discovery for patients with dilated cardiomyopathy
In a long-term collaboration, Ksilink and myriamed jointly established and validated an induced pluripotent stem cell (i…
Ksilink, joining academic-industry cell imaging consortium
The Joint Undertaking in Morphological Profiling with Cell Painting aims to accelerate drug discovery and development by…
Ksilink tritt renommiertem Konsortium für Zellbildgebung bei
Das Konsortium “Joint Undertaking in Morphological Profiling with Cell Painting” (JUMP-CP) zielt darauf ab, die Entdecku…
